FDA approves lumryz for narcolepsy

The U.S. Food & Drug Administration has approved Lumryz for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy. Lumryz is an extended-release formulation of sodium oxybate to be taken once ...


Sleep as a new eighth measure of cardiovascular health

Researchers at Columbia University Mailman School of Public Health evaluated an expanded measure of cardiovascular health (CVH) that includes sleep as an eighth metric, in relation to cardiovascular disease risk. This represents ...

Parkinson's & Movement disorders

Parkinson's disease: Bad dreams could be an early warning sign

Every night when we go to sleep, we spend a couple of hours in a virtual world created by our brains in which we are the main protagonist of an unfolding story we did not consciously create. In other words, we dream.

page 2 from 10